OptimizeRx (OPRX) Receivables - Other (2016 - 2026)

OptimizeRx (OPRX) has 10 years of Receivables - Other data on file, last reported at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 11.06% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (up 11.06% YoY), and the FY2025 full-year result was $3.9 million, up 21.66% from the prior year.
• Receivables - Other climbed to $4.7 million in Q1 2026, from $3.9 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $6.1 million in Q4 2023 to a low of $3.2 million in Q4 2024.
• A 5-year average of $4.3 million and a median of $3.9 million in 2025 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other soared 69.73% in 2022 and slumped 46.67% in 2024, its largest moves.
• Tracing OPRX's Receivables - Other over 5 years: stood at $3.6 million in 2022, then jumped by 69.62% to $6.1 million in 2023, then plunged by 46.67% to $3.2 million in 2024, then rose by 21.66% to $3.9 million in 2025, then grew by 19.43% to $4.7 million in 2026.
• Business Quant data shows OPRX's Receivables - Other at $4.7 million in Q1 2026, $3.9 million in Q4 2025, and $3.7 million in Q3 2025.